Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target
about
The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5ALipid kinases as therapeutic targets for chronic painPlasticity of PI4KIIIα interactions at the plasma membraneCinderella story: PI4P goes from precursor to key signaling moleculeMutations in tetratricopeptide repeat domain 7A result in a severe form of very early onset inflammatory bowel disease.Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factoriesGermline recessive mutations in PI4KA are associated with perisylvian polymicrogyria, cerebellar hypoplasia and arthrogryposisPhosphoinositides in the hepatitis C virus life cycle.Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses.Oxysterol-binding protein family I is the target of minor enviroxime-like compounds.Mutations in Encephalomyocarditis Virus 3A Protein Uncouple the Dependency of Genome Replication on Host Factors Phosphatidylinositol 4-Kinase IIIα and Oxysterol-Binding ProteinPhosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo.A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIβ.Pharmacological and genetic targeting of the PI4KA enzyme reveals its important role in maintaining plasma membrane phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate levels.Host-targeting agents in the treatment of hepatitis C: a beginning and an end?Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.Mammalian phosphatidylinositol 4-kinases as modulators of membrane trafficking and lipid signaling networks.Mapping of functional domains of the lipid kinase phosphatidylinositol 4-kinase type III alpha involved in enzymatic activity and hepatitis C virus replication.Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication.Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture.Tyrphostin AG1478 Inhibits Encephalomyocarditis Virus and Hepatitis C Virus by Targeting Phosphatidylinositol 4-Kinase IIIα.Mouse and human CRKL is dosage sensitive for cardiac outflow tract formation.Bialellic Mutations in Tetratricopeptide Repeat Domain 7A (TTC7A) Cause Common Variable Immunodeficiency-Like Phenotype with Enteropathy.A Forward Genetic Screen Targeting the Endothelium Reveals a Regulatory Role for the Lipid Kinase Pi4ka in Myelo- and Erythropoiesis.Current and future targets of antiviral therapy in the hepatitis C virus life cycle
P2860
Q21131379-A8682DB8-E6B1-4831-9557-42A5884BD027Q27023075-907122EE-1018-4D31-85AB-554E94217049Q28116252-A2F1647A-4AB0-42AB-822F-BF3D4566C49FQ28301748-6C0E9212-94BA-4E25-9D17-B8310D35E713Q34397488-A0F499B7-06FB-4810-ACA6-F898CD6CB945Q35385005-FF8F889D-3BCA-4D07-8A71-F9C2D4CFD122Q35693908-2B025238-52DB-48B3-88DA-36FB935DAEAFQ36395871-B94D8C12-BEC1-444D-ACE3-423D82C0B6B4Q36425870-1A9369E8-BEC3-42C7-A6FF-D756A38033E3Q36760237-73651BAB-1FA1-497B-8AAB-0ABA27A90597Q36956095-A31CE54A-BA9D-4572-85C9-93D060A2997CQ36970004-D059C028-0003-4F93-B403-D705862A3FF5Q37263877-3035F434-F808-4C88-B027-D8E8BA0801FEQ37608552-D4A2925C-F77D-4A32-89D8-F818D4B51342Q37676364-ACD72B8C-4353-4D50-B231-51D6731056BCQ37699395-6F77EE35-233B-4043-9ED5-1BB80BE2A64AQ38100883-6604E91F-F633-47E5-8F51-765F04E90A82Q38985647-48C7715B-A22F-4B7F-B91F-DACAB9C9C505Q39177306-E570FBDB-20F8-42C6-A816-BD02C35029FFQ40404561-79CD8ED5-DD08-4B09-AC21-2E5CCB3073D8Q40592568-1E06D578-3855-4360-9A19-E68E5D6E273BQ43136777-51E817C9-8787-4D11-B26C-3F8CD85AAAEFQ48238587-E738AAEA-EFDF-441E-9826-44051C1E6851Q49547319-85B3B550-399A-4C8F-B38C-3FF99CFC6C79Q57071775-DDCCA6F3-1FA4-493D-BAC0-667B991EE682
P2860
Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target
@ast
Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target
@en
type
label
Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target
@ast
Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target
@en
prefLabel
Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target
@ast
Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target
@en
P2093
P2860
P356
P1433
P1476
Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target
@en
P2093
Anne-Marie Faucher
Brian L Knight
Elias T Gaillard
Frédéric H Vaillancourt
George Kukolj
Huiping Jiang
James H Stoltz
Louise Pilote
Louiza Mahrouche
Lynn Pantages
P2860
P304
11595-11607
P356
10.1128/JVI.01320-12
P407
P577
2012-08-15T00:00:00Z